EFORL-R Stock Overview
Engages in the distribution of medical devices and equipment in Thailand.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
E for L Aim Public Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ฿0.15 |
52 Week High | ฿0.30 |
52 Week Low | ฿0.07 |
Beta | 1.14 |
11 Month Change | 15.38% |
3 Month Change | 50.00% |
1 Year Change | -34.78% |
33 Year Change | -93.18% |
5 Year Change | -62.50% |
Change since IPO | -93.12% |
Recent News & Updates
Recent updates
Shareholder Returns
EFORL-R | TH Healthcare | TH Market | |
---|---|---|---|
7D | 15.4% | -2.5% | 0.04% |
1Y | -34.8% | -5.7% | 2.8% |
Return vs Industry: EFORL-R underperformed the TH Healthcare industry which returned -5.7% over the past year.
Return vs Market: EFORL-R underperformed the TH Market which returned 2.8% over the past year.
Price Volatility
EFORL-R volatility | |
---|---|
EFORL-R Average Weekly Movement | 14.8% |
Healthcare Industry Average Movement | 4.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in TH Market | 10.9% |
10% least volatile stocks in TH Market | 2.5% |
Stable Share Price: EFORL-R's share price has been volatile over the past 3 months compared to the TH market.
Volatility Over Time: EFORL-R's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of TH stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | Preecha Nuntnarumit | www.eforl-aim.com |
E for L Aim Public Company Limited, together with its subsidiaries, engages in the distribution of medical devices and equipment in Thailand. The company offers clinical hematology, microscopy, chemistry, immunology, and microbiology related products. It also offers various equipment for medical devices.
E for L Aim Public Company Limited Fundamentals Summary
EFORL-R fundamental statistics | |
---|---|
Market cap | ฿599.77m |
Earnings (TTM) | -฿22.89m |
Revenue (TTM) | ฿1.16b |
0.5x
P/S Ratio-26.2x
P/E RatioIs EFORL-R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EFORL-R income statement (TTM) | |
---|---|
Revenue | ฿1.16b |
Cost of Revenue | ฿771.80m |
Gross Profit | ฿384.67m |
Other Expenses | ฿407.56m |
Earnings | -฿22.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0057 |
Gross Margin | 33.26% |
Net Profit Margin | -1.98% |
Debt/Equity Ratio | 74.9% |
How did EFORL-R perform over the long term?
See historical performance and comparison